Please login to the form below

Not currently logged in


This page shows the latest Insmed news and features for those working in and with pharma, biotech and healthcare.

Insmed claims first FDA okay for limited population antibiotic

Insmed claims first FDA okay for limited population antibiotic

Arikayce is cleared to treat lung disease caused by MAC. Insmed’s Arikayce has become the first antibiotic to be approved under a new FDA pathway that aims to encourage the ... For Insmed, the approval marks the end of a 10-year effort to develop

Latest news

  • Survival strategy

    Examples include Merck's $130m acquisition of Insmed's biologic facilities and pipeline, Mylan's deal with Biocon in 2009, Pfizer's $350m deal with Biocon for insulin biosimilars in October

  • Biogen Idec gains ALS drug

    In addition, under an FDA-approved programme, a limited number of people with ALS receive Insmed's Iplex, although the drug has not been granted marketing approval for the indication.

  • Biologics at forefront

    Novartis/Sandoz is already a major player in biosimilars while, last year, Merck acquired Insmed's portfolio of follow-on biologics for $130m in cash.

  • The Pump House

    Hepatitis. China. Mecasermin rinfabate. Iplex (Insmed). Growth disorders. US. Methylphenidate. Methylin Chewable Tablets (Alliant Pharmaceuticals).

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Significant figures Significant figures

    Insmed’s Olaf Bartsch tells PME about the US biotech’s year of progress. ... However, Insmed believes ALIS “has the opportunity to dramatically improve the treatment of NTM lung disease”.

  • Deal Watch October 2016 Deal Watch October 2016

    In the deal with Insmed the molecule is in phase I and has been licensed for development and commercialisation in an orphan indication to Insmed and AstraZeneca has retained the option ... 160. AstraZeneca (UK). Insmed. Licence. Dipeptidyl peptidase one

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Say Communications Say Communications

    Alimera Sciences. British Dupuytren's Society. Camcon Medical. Infant &Toddler Forum. Insmed.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...